Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
The first FDA-cleared device that supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our five FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without additional equipment, procedures or radiation dose.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
ClearRead CT and X-ray Applications, the Most Clinically Validated in the Industry, Help Maintain Efficiency, Accuracy and Consistency in Lung Cancer Screening
Riverain Technologies™, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, will showcase its solutions and enhancements at the 107th Annual Radiological Society of North America (RSNA) meeting, November 28-December 2, 2021 (South Hall #4129).
Key workflow enhancements are focused on improving the clinical user experience through tighter integration into site clinical processes for streamlined and more efficient reporting. For example, Fleischner and Lung-RADS scores can be customized to institutional or provider preferences and included in the case level summary report. Nodules can be sorted based on diameter, mass, volume, doubling time, etc. Standardized reports have been revised for configurability, language and readability with a configurable PDF output.
Clinical improvements to ClearRead solutions that continue to push the frontiers of nodule detection accuracy will be demonstrated for the first time. Nodule detection enhancements include enhanced performance on mediastinal nodules, nodule typing and nodule matching for better workflow.
In addition, the company will showcase updates to system service capabilities, making it easier for in-house teams to manage more service onsite.
For more information or to schedule an appointment, visit Riverain/RSNA.
ClearRead CT applications are approved for concurrent reading, saving radiologists time and steps in enhanced image review. The ClearRead suite significantly improves a clinician’s ability to accurately and efficiently detect disease using patented vessel (CT) and bone (X-ray) suppression technology in thoracic images—for earlier, more efficient detection of lung abnormalities.
“As our installed base continues to expand and customers implement enterprise level solutions, improvements to enhance clinical accuracy as well as efficient reporting are critical for optimized workflows. ClearRead tools utilize increased automation to help radiologists improve the efficiency of disease detection, diagnosis, reporting, and treatment,” said Mark Koeniguer, Chief Commercial Officer at Riverain Technologies.
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
|The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
|This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
|This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".